Tag Archives: GEOVAX COVID VACCINE TARGETING VIRUS IN TWO PLACES SHOWS PROMISE

An experimental vaccine developed by GeoVax Labs succeeded in promoting development of antibodies that target two different sites on the coronavirus in a small pilot study and has been advanced to mid-stage clinical trials, researchers reported. Like currently available COVID-19 vaccines, GeoVax’s GEO-CM04S1 induces immune responses that target the spike protein on the surface of the virus. But it also …

Read More »